About Us

The research group led by Dr Mark Bond at the University of Bristol focuses on uncovering the molecular mechanisms that drive cardiovascular disease and related conditions. Combining computational modelling, chemical biology, and experimental approaches, the team works to identify and characterise novel therapeutic targets, with a particular emphasis on transcriptional regulation and cell signalling pathways.

A key strength of the group lies in its integration of in silico drug discovery with laboratory validation, enabling the rapid development of innovative small molecules with potential clinical applications. Through interdisciplinary collaboration, the Bond Lab aims to translate fundamental scientific insights into tangible advances in treatment, contributing to improved outcomes for patients with cardiovascular and other chronic diseases.